After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)
After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)
AI 導讀
President and CEO Malte Peters summarizes the ESMO data for vopemetistat, which was in second and third line pancreatic cancer in combination with daraxonrasib, and discusses plans for a phase 3 in first line (plus the regulatory path for later lines as well). Additionally, he discusses using PRMT5 inhibition in lung cancer and GBM.
🎙️
Podcast 專家音訊節目
收錄於 888news Podcast 智庫專區，包含精華摘要與上市公司即時行情
正文 · AI 翻譯
Malte Peters 總裁兼執行長總結了 vopemetistat 在第二線及第三線胰臟癌與 daraxonrasib 組合的 ESMO 資料，並討論了在一線進行 III 期試驗的計畫（以及後續線別的監管路徑）。此外，他還討論了在肺癌和腦膠質母細胞瘤中使用 PRMT5 抑制劑。
來源： BiotechTV - News (podcasters.spotify.com)
開啟原文